c-Met/HGFR
Gli inibitori di c-Met/HGFR mirano al Recettore del Fattore di Crescita degli Epatociti (c-Met), una tirosina chinasi coinvolta in processi cellulari come crescita, motilità e morfogenesi. La segnalazione di c-Met è implicata nella progressione del cancro, nella metastasi e nella resistenza alle terapie. L'inibizione di c-Met può interrompere la crescita e la diffusione del tumore, rendendo questi inibitori preziosi nella ricerca sul cancro. Presso CymitQuimica, offriamo inibitori di c-Met/HGFR per supportare la tua ricerca in oncologia, metastasi e terapie oncologiche mirate.
Trovati 128 prodotti di "c-Met/HGFR"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Crizotinib
CAS:<p>Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.</p>Formula:C21H22Cl2FN5OPurezza:99% - 99.87%Colore e forma:SolidPeso molecolare:450.34AMG-208
CAS:<p>AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.</p>Formula:C22H17N5O2Purezza:98.56%Colore e forma:SolidPeso molecolare:383.4S49076
CAS:<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Formula:C22H22N4O4SPurezza:95.35% - 97.4%Colore e forma:SolidPeso molecolare:438.5DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Formula:C41H42FN5O7Purezza:99.75%Colore e forma:SolidPeso molecolare:735.8Capmatinib 2HCl
CAS:<p>Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.</p>Formula:C23H19Cl2FN6OPurezza:98.80%Colore e forma:SolidPeso molecolare:485.34SGX-523
CAS:<p>SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.</p>Formula:C18H13N7SPurezza:99% - >99.99%Colore e forma:SolidPeso molecolare:359.41BMS-794833
CAS:<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Formula:C23H15ClF2N4O3Purezza:98% - 99.69%Colore e forma:SolidPeso molecolare:468.84XL092
CAS:<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Formula:C29H25FN4O5Purezza:98.60%Colore e forma:SolidPeso molecolare:528.53SCR-1481B1
CAS:<p>SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor</p>Formula:C32H40ClF2N6O13PPurezza:98.07%Colore e forma:SolidPeso molecolare:821.12Amuvatinib
CAS:<p>Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.</p>Formula:C23H21N5O3SPurezza:99.38% - >99.99%Colore e forma:SolidPeso molecolare:447.51PHA-665752
CAS:<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Formula:C32H34Cl2N4O4SPurezza:97.05% - 98.82%Colore e forma:SolidPeso molecolare:641.61Capmatinib
CAS:<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formula:C23H17FN6OPurezza:99.24%Colore e forma:SolidPeso molecolare:412.42PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Formula:C19H16N8OPurezza:98.41% - 98.55%Colore e forma:SolidPeso molecolare:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Formula:C25H23FN8O2S2·HClPurezza:97.95%Colore e forma:SolidPeso molecolare:587JNJ-38877605
CAS:<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Formula:C19H13F2N7Purezza:97.04% - 98.27%Colore e forma:SolidPeso molecolare:377.35Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Formula:C30H22F2N6O3Purezza:95% - 99.71%Colore e forma:SolidPeso molecolare:552.53MGCD-265 analog
CAS:<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Formula:C26H20FN5O2S2Purezza:98.06% - 98.68%Colore e forma:SolidPeso molecolare:517.6Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Formula:C17H15N9Purezza:98.12%Colore e forma:SolidPeso molecolare:345.36Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Formula:C23H18ClFN6OPurezza:98.62% - 99.81%Colore e forma:SolidPeso molecolare:448.89SRI 31215 TFA
CAS:<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Formula:C27H34F3N5O3Purezza:98.25% - 99.97%Colore e forma:SolidPeso molecolare:533.6Cabozantinib
CAS:<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Formula:C28H24FN3O5Purezza:99.68% - 99.88%Colore e forma:SolidPeso molecolare:501.51(Z)-Semaxinib
CAS:<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Formula:C15H14N2OPurezza:98.82% - ≥95%Colore e forma:SolidPeso molecolare:238.28Cabozantinib hydrochloride
CAS:<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Formula:C28H25ClFN3O5Purezza:99.97%Colore e forma:SolidPeso molecolare:537.96BAY-474
CAS:<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Formula:C17H15N5Purezza:98.98%Colore e forma:SolidPeso molecolare:289.33Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Formula:C24H25ClFN5O3Purezza:98.56% - 99.9%Colore e forma:Off-White SolidPeso molecolare:485.94Amivantamab
CAS:<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Purezza:97.24% (SEC-HPLC) - 99.74%Colore e forma:LiquidPeso molecolare:145.88 kDaFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Purezza:95%Colore e forma:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Purezza:98%Colore e forma:LiquidBafisontamab
CAS:<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Colore e forma:LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Formula:C20H11Cl2N3OPurezza:98%Colore e forma:SolidPeso molecolare:380.23SU11274
CAS:<p>SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.</p>Formula:C28H30ClN5O4SPurezza:98.62% - 99.53%Colore e forma:Orange PowderPeso molecolare:568.09AMG-458
CAS:<p>AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.</p>Formula:C30H29N5O5Purezza:99.91% - 99.98%Colore e forma:SolidPeso molecolare:539.58Glesatinib
CAS:<p>Glesatinib is an orally active and potent dual inhibitor of MET/SMO.</p>Formula:C31H27F2N5O3S2Purezza:98%Colore e forma:SolidPeso molecolare:619.7Dalmelitinib
CAS:<p>Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.</p>Formula:C22H16FN7O2SColore e forma:SolidPeso molecolare:461.47c-Met-IN-16
CAS:<p>c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .</p>Formula:C21H17F2N9OColore e forma:SolidPeso molecolare:449.42ABN401
CAS:<p>ABN401: potent c-MET inhibitor (IC50: 10 nM), cytotoxic to MET-dependent cancers, blocks tumor c-MET phosphorylation, for cancer research.</p>Formula:C29H34N12OColore e forma:SolidPeso molecolare:566.66AC-386
CAS:<p>AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.</p>Formula:C35H34FN5O6Colore e forma:SolidPeso molecolare:639.67Tyrosine kinase-IN-4
CAS:<p>Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].</p>Formula:C23H21N3O3Colore e forma:SolidPeso molecolare:387.43LCRF-0004
CAS:<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Formula:C28H18F4N6O2SColore e forma:SolidPeso molecolare:578.54c-Met-IN-13
CAS:<p>c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.</p>Formula:C30H28F2N2O6Colore e forma:SolidPeso molecolare:550.55SAR125844
CAS:<p>SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)</p>Formula:C25H23FN8O2S2Purezza:98.73%Colore e forma:SolidPeso molecolare:550.63c-Met-IN-11
CAS:<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Formula:C30H20F2N4O3Colore e forma:SolidPeso molecolare:522.5Glesatinib hydrochloride
CAS:<p>Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.</p>Formula:C31H28ClF2N5O3S2Purezza:98%Colore e forma:SolidPeso molecolare:656.16Axl-IN-8
CAS:<p>Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).</p>Formula:C31H29FN6O3Colore e forma:SolidPeso molecolare:552.6T-1840383
CAS:<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Formula:C30H25ClFN5O4Colore e forma:SolidPeso molecolare:574MK-8033 hydrochloride
CAS:<p>MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.</p>Formula:C25H22ClN5O3SColore e forma:SolidPeso molecolare:507.99Mifanertinib dimaleate
CAS:<p>Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formula:C29H27ClF3N5O10Colore e forma:SolidPeso molecolare:698c-Met-IN-12
CAS:<p>c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.</p>Formula:C34H29FN4O4Colore e forma:SolidPeso molecolare:576.62Boditrectinib
CAS:<p>Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.</p>Formula:C23H24F2N6OColore e forma:SolidPeso molecolare:438.47Mifanertinib
CAS:<p>Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formula:C21H19ClF3N5O2Colore e forma:SolidPeso molecolare:465.86
